Iron carboxymaltose in the treatment of iron deficiency/ anaemia in patients with IBD

1. Andrews NC. Disorders of iron metabolism. N Engl J Med 1999; 341 (26): 1986–1995. doi: 10.1056/NEJM199912233412607.

2. Wang J, Pantopoulos K. Regulation of cellular iron metabolism. Biochem J 2011; 434 (3): 365–381. doi: 10.1042/BJ20101825.

3. Nemeth E, Ganz T. The role of hepcidin in iron metabolism. Acta Haematol 2009; 122 (2–3): 78–86. doi: 10.1159/000243791.

4. Vifor. Ferinject. SmPC 2020.

5. Anker SD, Comin Colet J, Filippatos G et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009; 361 (25): 2436–2448. doi: 10.1056/NEJMoa0908 355.

6. Ponikowski P, van Veldhuisen DJ, Comin-Colet J et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J 2015; 36 (11): 657–668. doi: 10.1093/eurheartj/ehu385.

7. van Veldhuisen DJ, Ponikowski P, van der Meer P et al. Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. Circulation 2017; 136 (15): 1374–1383. doi: 10.1161/ CIRCULATIONAHA.117.027497.

8. Ponikowski P, Kirwan BA, Anker SD et al. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet 2020; 396 (10266): 1895–1904. doi: 10.1016/S0140-6736 (20) 32339-4.

9. Mentz RJ, Garg J, Rockhold FW et al. Ferric carboxymaltose in heart failure with iron deficiency. N Engl J Med 2023; 389 (11): 975–986. doi: 10.1056/NEJMoa2304968.

10. Kulnigg S, Stoinov S, Simanenkov V et al. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. Am J Gastroenterol 2008; 103 (5): 1182–1192. doi: 10.1111/ j.1572-0241.2007.01744.x.

11. Evstatiev R, Marteau P, Iqbal T et al. FERGI- cor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology 2011; 141 (3): 846–853. doi: 10.1053/ j.gastro.2011.06.005.

12. Evstatiev R, Alexeeva O, Bokemeyer B et al. Ferric carboxymaltose prevents recurrence of anemia in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013; 11 (3): 269–277. doi: 10.1016/j.cgh.2012.10.013.

13. Kulnigg-Dabsch S, Schmid W, Howaldt S et al. Iron deficiency generates secondary thrombocytosis and platelet activation in IBD: the randomized, controlled thromboVIT trial. Inflamm Bowel Dis 2013; 19 (8): 1609–1616. doi: 10.1097/ MIB.0b013e318281f4db.

14. Qunibi WY, Martinez C, Smith M et al. A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients. Nephrol Dial Transplant 2011; 26 (5): 1599–1607. doi: 10.1093/ndt/gfq613.

15. Charytan C, Bernardo MV, Koch TA et al. Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease: a randomized, active-controlled, multi-center study. Nephrol Dial Transplant 2013; 28 (4): 953–964. doi: 10.1093/ndt/gfs528.

16. Onken JE, Bregman DB, Harrington RA et al. Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial. Nephrol Dial Transplant 2014; 29 (4): 833–842. doi: 10.1093/ndt/ gft251.

17. Macdougall IC, Bock AH, Carrera F et al. FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrol Dial Transplant 2014; 29 (11): 2075–2084. doi: 10.1093/ndt/gfu201.

18. Ikuta K, Hanashi H, Hirai K et al. Comparison of efficacy and safety between intravenous ferric carboxymaltose and saccharated ferric oxide in Japanese patients with iron-deficiency anemia due to hypermenorrhea: a multi-center, randomized, open-label noninferiority study. Int J Hematol 2019; 109 (1): 41–49. doi: 10.1007/s12185-018-2501-8.

19. Van Wyck DB, Martens MG, Seid MH et al. Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial. Obstet Gynecol 2007; 110 (2 Pt 1): 267–278. doi: 10.1097/01.AOG.0000275286.03283.

18. Breymann C, Milman N, Mezzacasa A et al. Ferric carboxymaltose vs. oral iron in the treatment of pregnant women with iron deficiency anemia: an international, open-label, randomized controlled trial (FER-ASAP). J Perinat Med 2017; 45 (4): 443–453. doi: 10.1515/jpm-2016-0050.

21. Seid MH, Derman RJ, Baker JB et al. Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anemia: a randomized controlled clinical trial. Am J Obstet Gynecol 2008; 199 (4): 435.e1–435.e7. doi: 10.1016/ j.ajog.2008.07.046.

22. Van Wyck DB, Mangione A, Morrison J et al. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial. Transfusion 2009; 49 (12): 2719–2728. doi: 10.1111/j.1537-2995.2009.02327.x.

23. Favrat B, Balck K, Breymann C et al. Evaluation of a single dose of ferric carboxymaltose in fatigued, iron-deficient women-PREFER a randomized, placebo-controlled study. PLoS One 2014; 9 (4): e94217. doi: 10.1371/journal.pone.0094217.

24. Breymann C, Gliga F, Bejenariu C et al. Comparative efficacy and safety of intravenous ferric carboxymaltose in the treatment of postpartum iron deficiency anemia. Int J Gynaecol Obstet 2008; 101 (1): 67–73. doi: 10.1016/j.ijgo.2007.10.009.

25. Seid MH, Butcher AD, Chatwani A. Ferric carboxymaltose as treatment in women with iron-deficiency anemia. Anemia 2017; 2017: 9642027. doi: 10.1155/2017/9642027.

26. Allen RP, Adler CH, Du W et al. Clinical efficacy and safety of IV ferric carboxymaltose (FCM) treatment of RLS: a multi-centred, placebo-controlled preliminary clinical trial. Sleep Med 2011; 12 (9): 906–913. doi: 10.1016/j.sleep.2011.06.009.

28. Hedenus M, Karlsson T, Ludwig H et al. Intravenous iron alone resolves anemia in patients with functional iron deficiency and lymphoid malignancies undergoing chemotherapy. Med Oncol 2014; 31 (12): 302. doi: 10.1007/s12032-014-0302-3.

29. Bailie GR, Mason NA, Valaoras TG. Safety and tolerability of intravenous ferric carboxymaltose in patients with iron deficiency anemia. Hemodial Int 2010; 14 (1): 47–54. doi: 10.1111/j.1542-4758.2009.00409.x.

30. Geisser P, Banké-Bochita J. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia. Arzneimittelforschung 2010; 60 (6a): 362–372. doi: 10.1055/s-0031-1296301.

31. Barish CF, Koch T, Butcher A et al. Safety and efficacy of intravenous ferric carboxymaltose (750 mg) in the treatment of iron deficiency anemia: two randomized, controlled trials. Anemia 2012; 2012: 172104. doi: 10.1155/2012/172104.

32. Hussain I, Bhoyroo J, Butcher A et al. Direct comparison of the safety and efficacy of ferric carboxymaltose versus iron dextran in patients with iron deficiency anemia. Anemia 2013; 2013: 169107. doi: 10.1155/2013/169107.

33. Onken JE, Bregman DB, Harrington RA et al. A multicenter, randomized, active-controlled study to investigate the efficacy and safety of intravenous ferric carboxymaltose in patients with iron deficiency anemia. Transfusion 2014; 54 (2): 306–315. doi: 10.1111/trf.12289.

34. Boomershine CS, Koch TA, Morris D. A blinded, randomized, placebo-controlled study to investigate the efficacy and safety of ferric carboxymaltose in iron-deficient patients with fibromyalgia. Rheumatol Ther 2018; 5 (1): 271–281. doi: 10.1007/s40744-017-0088-9.

35. Dignass AU, Gasche C, Bettenworth D et al. European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. J Crohns Colitis 2015; 9 (3): 211–222. doi: 10.1093/ecco-jcc/jju009.

36. Aksan A, Işık H, Radeke HH et al. Systematic review with network meta-analysis: comparative efficacy and tolerability of different intravenous iron formulations for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2017; 45 (10): 1303–1318. doi: 10.1111/apt.14043.

37. Befrits R, Wikman O, Blomquist L et al. Anemia and iron deficiency in inflammatory bowel disease: an open, prospective, observational study on diagnosis, treatment with ferric carboxymaltose and quality of life. Scand J Gastroenterol 2013; 48 (9): 1027–1032. doi: 10.3109/00365521.2013.819442.

38. Cortes X, Borrás-Blasco J, Molés JR et al. Safety of ferric carboxymaltose immediately after infliximab administration, in a single session, in inflammatory bowel disease patients with iron deficiency: a pilot study. PLoS One 2015; 10 (5): e0128156. doi: 10.1371/journal.pone.0128156.

39. García-López S, Bocos JM, Gisbert JP et al. High-dose intravenous treatment in iron deficiency anaemia in inflammatory bowel disease: early efficacy and impact on quality of life. Blood Transfus 2016; 14 (2): 199–205. doi: 10.2450/2016.0246-15.

40. Stein J, Aksan A, Klemm W et al. Safety and efficacy of ferric carboxymaltose in the treatment of iron deficiency anaemia in patients with inflammatory bowel disease, in routine daily practice. J Crohns Colitis 2018; 12 (7): 826–834. doi: 10.1093/ecco-jcc/jjy042.

41. Sobrado CW, Cançado RD, Sobrado LF et al. Treatment of anemia and improvement of quality of life among patients with Crohn‘s disease: experience using ferric carboxymaltose. Arq Gastroenterol 2015; 52 (4): 255–259. doi: 10.1590/S0004-28032015000400002.

42. Hrdlička L, Kohout P, Liberda M et al. Doporučený postup pro diagnostiku a léčbu anémie u IBD. Gastroent Hepatol 2012; 66 (4): 280–285.

43. Přehled léčiv. SPC Ferinject. 2024 [online]. Dostupné z: https: //prehledy.sukl.cz/prehled_leciv.html#/detail-reg/0155378.

44. SÚKL. Změna registrace léčivého přípravku FERINJECT 50 mg/ml injekční/infuzní disperze. 2024 [online]. Dostupné z: https: //sukl.gov.cz/registrace-leciv/informace-o-vyznamnych-zmenach-registrace/zmena-registrace-leciveho-pripravku-ferinject-50- mg- ml-injekcni-infuzni-disperze/.

45. Přehled léčiv. Detail varianty léčivého přípravku FERINJECT. 2024 [online]. Dostupné z: https: //prehledy.sukl.cz/prehled_leciv.html#/leciva/0155379.

Korespondenční autorka

MUDr. Michaela Bachratá

Care Comm s. r. o.

K publikaci schválil

prof. MUDr. Milan Lukáš, CSc., AGAF

šéfredaktor GH